{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:01:03Z","timestamp":1787022063195,"version":"build-2736575974"},"reference-count":28,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Merck Serono GmbH"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0231846","type":"journal-article","created":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T13:24:52Z","timestamp":1588339492000},"page":"e0231846","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":30,"title":["Epidemiology, characteristics and treatment of patients with relapsing remitting multiple sclerosis and incidence of high disease activity: Real world evidence based on German claims data"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2868-5211","authenticated-orcid":true,"given":"Christoph","family":"Ohlmeier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Gothe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Osowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina","family":"Weinhold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Blauwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Schmedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Galetzka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Berkemeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Tackenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Stangel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,5,1]]},"reference":[{"key":"pone.0231846.ref001","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/B978-0-444-52001-2.00010-8","article-title":"The epidemiology of multiple sclerosis: insights to disease pathogenesis","volume":"122","author":"DS Goodin","year":"2014","journal-title":"Handb Clin Neurol"},{"key":"pone.0231846.ref002","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"FD Lublin","year":"2014","journal-title":"Neurology"},{"key":"pone.0231846.ref003","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1177\/1756285613484079","article-title":"Magnetic resonance monitoring of lesion evolution in multiple sclerosis","volume":"6","author":"A Rovira","year":"2013","journal-title":"Ther Adv Neurol Disord"},{"key":"pone.0231846.ref004","unstructured":"Multiple Sclerosis International Federation (2013) Atlas of MS 2013: Mapping Multiple Sclerosis around the World."},{"key":"pone.0231846.ref005","unstructured":"Holstiege J, Steffen A, Goffrie B, B\u00e4tzing J (2017) Epidemiology of multiple sclerosis\u2014a population-based, Germany-wide study."},{"key":"pone.0231846.ref006","first-page":"113","article-title":"Multiple sclerosis registry in Germany: results of the extension phase 2005\/2006","volume":"105","author":"P Flachenecker","year":"2008","journal-title":"Dtsch Arztebl Int"},{"key":"pone.0231846.ref007","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/1352458517708141","article-title":"New insights into the burden and costs of multiple sclerosis in Europe","volume":"23","author":"P Flachenecker","year":"2017","journal-title":"Results for Germany. Mult Scler"},{"key":"pone.0231846.ref008","unstructured":"Deutsche Gesellschaft f\u00fcr Neurologie (2014) Diagnose und Therapie der Multiplen Sklerose."},{"key":"pone.0231846.ref009","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","article-title":"Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology","volume":"90","author":"A Rae-Grant","year":"2018","journal-title":"Neurology"},{"key":"pone.0231846.ref010","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/ene.13536","article-title":"ECTRIMS\/EAN guideline on the pharmacological treatment of people with multiple sclerosis","volume":"25","author":"X Montalban","year":"2018","journal-title":"Eur J Neurol"},{"key":"pone.0231846.ref011","doi-asserted-by":"crossref","first-page":"1756285617749802","DOI":"10.1177\/1756285617749802","article-title":"An epidemiological study on the course of disease and therapeutic considerations in relapsing-remitting multiple sclerosis patients receiving injectable first-line disease-modifying therapies in Germany (EPIDEM)","volume":"11","author":"S Schmidt","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"key":"pone.0231846.ref012","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/pds.3895","article-title":"Characteristics and external validity of the German Health Risk Institute (HRI) Database","volume":"25","author":"F Andersohn","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"pone.0231846.ref013","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1212\/WNL.0000000000000355","article-title":"MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study","volume":"82","author":"RJ Fox","year":"2014","journal-title":"Neurology"},{"key":"pone.0231846.ref014","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/1472-6963-13-131","article-title":"Resource utilization, costs and treatment patterns of switching and discontinuing treatment of MS patients with high relapse activity","volume":"13","author":"K Raimundo","year":"2013","journal-title":"BMC Health Serv Res"},{"key":"pone.0231846.ref015","doi-asserted-by":"crossref","first-page":"618","DOI":"10.3111\/13696998.2010.523670","article-title":"Medical chart validation of an algorithm for identifying multiple sclerosis relapse in healthcare claims","volume":"13","author":"BJ Chastek","year":"2010","journal-title":"J Med Econ"},{"key":"pone.0231846.ref016","doi-asserted-by":"crossref","first-page":"469","DOI":"10.18553\/jmcp.2002.8.6.469","article-title":"Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population","volume":"8","author":"DA Ollendorf","year":"2002","journal-title":"J Manag Care Pharm"},{"key":"pone.0231846.ref017","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"H Quan","year":"2005","journal-title":"Med Care"},{"key":"pone.0231846.ref018","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1093\/oxfordjournals.aje.a009523","article-title":"Confidence limits made easy: interval estimation using a substitution method","volume":"147","author":"LE Daly","year":"1998","journal-title":"Am J Epidemiol"},{"key":"pone.0231846.ref019","article-title":"Symptomatology and symptomatic treatment in multiple sclerosis: Results from a nationwide MS registry","author":"PS Rommer","year":"2018","journal-title":"Mult Scler"},{"key":"pone.0231846.ref020","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s15016-018-6423-8","article-title":"MS in Deutschland: Symptome und Behandlungsdefizite: Aktuelle Daten aus dem MS-Reguster der DMSG f\u00fcr die MS-Forschung","volume":"29","author":"U Zettl","year":"2018","journal-title":"NeuroTransmitter"},{"key":"pone.0231846.ref021","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1136\/jnnp.2008.145805","article-title":"Relapses in multiple sclerosis are age- and time-dependent","volume":"79","author":"H Tremlett","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"pone.0231846.ref022","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.clineuro.2014.09.008","article-title":"Relapsing multiple sclerosis patients treated with disease modifying therapy exhibit highly variable disease progression: a predictive model","volume":"127","author":"TF Scott","year":"2014","journal-title":"Clin Neurol Neurosurg"},{"key":"pone.0231846.ref023","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1186\/1472-6963-14-381","article-title":"Multiple sclerosis in Germany: data analysis of administrative prevalence and healthcare delivery in the statutory health system","volume":"14","author":"A Hoer","year":"2014","journal-title":"BMC Health Serv Res"},{"key":"pone.0231846.ref024","unstructured":"Stahmann A, Buckow K, Ellenberger D, Heymann D, Mai M, et al. The German MS Register: update on immunotherapy; 2016."},{"key":"pone.0231846.ref025","first-page":"990","article-title":"Epidemiology of multiple sclerosis in Germany: regional differences and drug prescription in the claims data of the statutory health insurance","volume":"85","author":"G Petersen","year":"2014","journal-title":"Nervenarzt"},{"key":"pone.0231846.ref026","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s11096-013-9857-x","article-title":"Treatment of multiple sclerosis in Germany: an analysis based on claims data of more than 30,000 patients","volume":"35","author":"R Windt","year":"2013","journal-title":"Int J Clin Pharm"},{"key":"pone.0231846.ref027","doi-asserted-by":"crossref","first-page":"e446","DOI":"10.1212\/NXI.0000000000000446","article-title":"Treatment choices and neuropsychological symptoms of a large cohort of early MS","volume":"5","author":"O von Bismarck","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"pone.0231846.ref028","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.msard.2017.07.003","article-title":"Is there a change of paradigm towards more effective treatment early in the course of apparent high-risk MS?","volume":"17","author":"O Fernandez","year":"2017","journal-title":"Mult Scler Relat Disord"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0231846","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T01:32:56Z","timestamp":1615512776000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0231846"}},"subtitle":[],"editor":[{"given":"Sreeram V.","family":"Ramagopalan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,5,1]]},"references-count":28,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,5,1]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0231846","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,1]]}}}